home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  September 22, 2020
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 501 active entries

BioProtein Tecnologies

63-65 Boulevard Massena
Paris, 75013, FRANCE

Phone: 33 1 44 06 0616
Fax: 33 1 44 06 75 25

E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


About BioProtein Technologies

BioProtein is the world leader in the production of recombinant proteins in the milk of transgenic rabbits. Rabbits offer great advantages in terms of scale-up and time-to-market and can produce up to 6-8 litres of milk per year. From the annual production of 400 rabbits, 5-10 kg of protein can be isolated and purified to a very high quality
BioProtein has a strong expertise through the entire manufacturing process from genes or cDNA expression to animal production. The Company has produced complex and difficult-to-express proteins, including monoclonal antibodies, hormones and vaccinating antigens, all of which demonstrates the company’s ability to fulfil the most rigorous specifications in protein production.

Our Mission

BioProtein’s mission is to provide the pharmaceutical and biotechnology industries with therapeutic proteins manufactured in the milk of transgenic rabbits.

Science and Technology

BioProtein uses its proprietary technologies to generate transgenic rabbits expressing defined proteins in their milk. These defined proteins are coded by specific genes provided by a partner or discovered by the Company.

BioProtein benefits from the invaluable know-how developed at INRA, the French Agronomy Research Institute that created the world’s first transgenic cattle in 1999. This expertise is the result of 15 years of research and has created the base for a sound technology platform in this field.

This exclusive partnership with INRA ensures BioProtein will remain at the forefront of cutting edge technologies that are applied for generating recombinant therapeutic proteins in transgenic animals.


BioProtein has a privileged partnership with INRA that provides the Company with:

- Know-how transfer, particularly in molecular biology, developmental biology and animal production
- Exclusive access to intellectual property: an exclusive licence for the applications of proteins produced in milk
- Logistic support, laboratory and staff resources

INRA is one of the most important research institutes in France; it has a budget of €520 million, 10,000 employees and 150 patents and breeders rights covering 500-marketed commercial crops.

Last update of this entry: February 04, 2002

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2020 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.